期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 18, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/ijms18081786
关键词
antibody; cancer therapy; therapeutic target; tumor; tumor angiogenesis; VEGF
资金
- Scripps Korea Antibody Institute [10TS03]
- Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIP) [2015M3A9 D9074279]
Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by the complicated and coordinated actions of pro-angiogenic factors and their receptors that become upregulated during tumorigenesis. Over the past several decades, vascular endothelial growth factor (VEGF) signaling has been identified as a central axis in tumor angiogenesis. The remarkable advent of recombinant antibody technology has led to the development of bevacizumab, a humanized antibody that targets VEGF and is a leading clinical therapy to suppress tumor angiogenesis. However, despite the clinical efficacy of bevacizumab, its significant side effects and drug resistance have raised concerns necessitating the identification of novel drug targets and development of novel therapeutics to combat tumor angiogenesis. This review will highlight the role and relevance of VEGF and other potential therapeutic targets and their receptors in angiogenesis. Simultaneously, we will also cover the current status of monoclonal antibodies being developed to target these candidates for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据